Immuron - ADR Share Price Today

Immuron Q1FY27 Results: Global revenue rises 9% YoY to AUD 2.2 million

Global product revenue rose 9% YoY to AUD 2.2 million in Q1FY27. Australian revenue grew 14% YoY, driven by Travelan® relaunch. US revenue fell 19% YoY due to resolved logistics delays; Canada rose 286%. FY26 net loss narrowed by AUD 1.4 million to AUD 3.8 million. Cash balance of AUD 9.0 million expected to fund operations through FY2028.

Immuron stock surges 58% as US PROIBS deal with Calmino expands market reach

Immuron shares surged 57.66% to $1.75 in premarket trading on Friday. Company signed exclusive US distribution deal for PROIBS with Calmino group AB. Deal targets $4.16 billion US digestive health supplement market. Usability study showed 94% of users found PROIBS helpful for gut health issues.

Immuron FY26 Results: Record sales of A$7.7m, profit up A$1.4m

Record FY26 net sales reached A$7.7 million, a 6% increase over the prior year. Net profit improved by A$1.4 million, exceeding strategic reset projections. Australian sales grew 10% despite inventory reductions by key retailer Chemist Warehouse. US sales rose 13% in USD terms; Canada saw >100% growth in H2 FY26. Cash position increased by A$6.2 million to A$9.0 million as of June 30, 2026.

Immuron CEO presents at Kalkine Media Webinar

Immuron Limited CEO Steven Lydeamore presented at the Kalkine Media Webinar on July 20, 2026, highlighting the company's biopharmaceutical developments. Key products include Travelan® for travelers’ diarrhea, IMM-529 for recurrent Clostridioides difficile infection, and ProIBS® for irritable bowel syndrome. The company’s platform technology focuses on orally delivered targeted polyclonal antibodies for infectious diseases.

Immuron FY26 sales rise 6% to AUD$7.7 million led by Australia

Immuron Limited achieved four consecutive quarters of sales growth in FY26, with global revenue rising 6% to AUD$7.7 million. Growth was led by Australian sales, which increased 10% to AUD$5.8 million, supported by digital marketing and store expansion. U.S. sales grew 7% in AUD terms to AUD$1.8 million, while Canadian sales showed a strong second-half recovery after a prior year pipeline fill.

Immuron hires Pullan to find partner for gut infection drug

Immuron Limited has engaged Pullan Consulting to find a strategic partner for IMM-529, a Phase 2 treatment for Clostridioides difficile infection (CDI), with projected revenues of US$400M. The company holds FDA IND approval and aims to leverage the firm's expertise to advance the polyclonal antibody therapy through clinical development and commercialization.